ReferenceID 2891
Stigmasterol stimulates transintestinal cholesterol excretion independent of liver X receptor activation in the small intestine
J Nutr Biochem
Despite advances in healthcare, cardiovascular disease (CVD) remains the leading cause of death in the United States. Elevated levels of plasma cholesterol are highly predictive of CVD and stroke and are the principal dr
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 2891
- Evidence Id
- 19481
- Core Evidence Id
- 19481
- Source Reference Id
- 5769
- Herb2 Reference Id
- HBREF006566
- Subject Paper Key
- HBIN044918_31759199
- Pubmed Id
- 31759199
- Doi
- 10.1016/j.jnutbio.2019.108263
- Paper Title
- Stigmasterol stimulates transintestinal cholesterol excretion independent of liver X receptor activation in the small intestine
- Paper Abstract
- Despite advances in healthcare, cardiovascular disease (CVD) remains the leading cause of death in the United States. Elevated levels of plasma cholesterol are highly predictive of CVD and stroke and are the principal driver of atherosclerosis. Unfortunately, current cholesterol lowering agents, such as statins, are not known to reverse atherosclerotic disease once it has been established. In preclinical models, agonists of nuclear receptor, LXR, have been shown to reduce and reverse atherosclerosis. Phytosterols are bioactive non-cholesterol sterols that act as LXR agonists and regulate cholesterol metabolism and transport. We hypothesized that stigmasterol would act as an LXR agonist and alter intestinal cholesterol secretion to promote cholesterol elimination. Mice were fed a control diet, or a diet supplemented with stigmasterol (0.3% w/w) or T0901317 (0.015% w/w), a known LXR agonist. In this experiment we analyzed the sterol content of bile, intestinal perfusate, plasma, and feces. Additionally, the liver and small intestine were analyzed for relative levels of transcripts known to be regulated by LXR. We observed that T0901317 robustly promoted cholesterol elimination and acted as a strong LXR agonist. Stigmasterol promoted transintestinal cholesterol secretion through an LXR-independent pathway.
- Journal
- J Nutr Biochem
- Publish Year
- 2020
- Experiment Subject
- mouse
- Experiment Type
- Animal Experiment
- Phenotype Related
- Atherosclerotic Disease; Stroke; Cardiovascular Disease; Atherosclerosis
- Paper Title Cn
- Paper Title En
- Stigmasterol stimulates transintestinal cholesterol excretion independent of liver X receptor activation in the small intestine
- Bilingual Status
- semi_complete